The Chronicle of Skin & Allergy - October/November 2023

Page 1

Contact allergens

P RACTICAL T HERAPEUTICS and C LINICAL N EWS from the W ORLD of D ERMATOLOGY

n

Nickel remains the number one contact O ./N . 2023 allergen CT

OV

n Aluminum, the

New AD Tx options

American Contact Dermatitis Society’s Allergen of the Year in 2022, is present in Hep A, Hep B, HPV, and DTaP vaccines

All rights reserved. Chronicle Information Resources Ltd. Canada Post Canadian Publications Mail Sales Product Agreement Number 40016917

by JOHN EVANS, Senior Editor, The Chronicle

N

◼ Dupilumab approved for pediatric patients over 6 months of age

see page 4

Psoriasis research

Advances in Txs for psoriasis n New topicals an option for patients who may be needle-phobic by LOUISE GAGNON, Correspondent, The Chronicle

T

he ability of roflumilast to offer efficacy as a foam, oral forms of IL inhibitors under investigation, long-term data on the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib, and data on the ability of spesolimab to prevent flares in generalized pustular psoriasis (GPP) are among the recent developments in psoriasis. A versatile topical for plaque PsO The 0.3% foam formulation of the

phosphodiesterase-4 inhibitor roflumilast demonstrated efficacy in a study to treat the scalp and other hair-bearing areas of the body. It provided better efficacy than vehicle as measured by various outcomes including Body-Investigator Global Dr. Irina Assessment and Turchin Scalp-Investigator Global Assessment. The foam was also found to be well-tolerated.

“Because it is non-steroidal, there is not a concern about local adverse events,” said Dr. Irina Turchin, Assistant Professor in the Division of Clinical Dermatology & Cutaneous Science, Department of Medicine, Dalhousie University in Halifax and Memorial University in St. John’s, N.L., and a dermatology consultant for Horizon Health Network in Fredericton, N.B. “There is no irritation when it is used in the skin folds. It is very well-tolerated. The other thing that we have seen in our patients is the reduction in pruritus.” Dr. Ashley O’Toole, a dermatolo-

ickel remains the king of contact allergens, Canadian regulations may have stemmed the rise of methylisothiazolinone (MI) and methylchloroisothiazolinone (MCI), and there are increasing rates of sensitivity to hydroperoxides of linalool and limonene. These were some of the findings from a recent summary of patch test results from the North American Contact Dermatitis Group (NACDG) (Dermatitis March-April 2023; 34(2):90-104) presented by Dr. Joel DeKoven during a webinar in April 2023. Dr. Dekoven was lead author on the paper. Toronto-based Dr. DeKoven, a consultant dermatologist, Professor in the Department Dr. Joel DeKoven of Medicine at the University of Toronto and President of the NACDG, presented the findings at

Please turn to New Tx page 11

Wound care

Diabetic foot ulcers in Indigenous populations n Limb amputations three times more common in Northern Ontario by KRISHNA RAU, Correspondent, The Chronicle

I

ndigenous communities have extremely high rates of type 2 diabetes and foot amputations, Dr. Gary Sibbald reported during a presentation at the second annual Indigenous Skin Spectrum Summit. More testing and foot examinations are needed in these communities. Dr. Sibbald is a Professor of Please turn to ISSS page 8

Connect with The Chronicle on

www.derm.city “Where Dermatology Lives” n Share your experiences and observations with a worldwide community of practitioners and researchers. Follow developments in skin health as they occur. Visit www.derm.city

Please turn to Contact page 18


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.